Dr Lloyd on the Effects of ESR1 Mutations on Elacestrant Outcomes in HR+ Advanced Breast Cancer
Автор: OncLive
Загружено: 2024-12-12
Просмотров: 307
Описание:
Maxwell Lloyd, MD, discusses a real-world study of elacestrant outcomes based on prior treatment and ESR1 mutation status in HR+ breast cancer.
Maxwell Lloyd, MD, clinical fellow, medicine, Department of Medicine, Beth Israel Deaconess Medical Center, discusses findings from a real-world study investigating the effects of prior treatment, ESR1 mutation status, and PI3K pathway mutation status on outcomes with elacestrant (Orserdu) monotherapy in patients with hormone receptor (HR)–positive, HER2-negative advanced breast cancer.
See more from SABCS on our site: https://www.onclive.com/conference/sabcs
Website: https://www.onclive.com
Twitter: / onclive
Facebook: / onclive
LinkedIn: / onclive
Повторяем попытку...
Доступные форматы для скачивания:
Скачать видео
-
Информация по загрузке:
